

Emily M Jutkiewicz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2947476/emily-m-jutkiewicz-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

1,430
citations

23
h-index

37
g-index

65
ext. papers

1,629
ext. citations

4.5
avg, IF

4.46
L-index

#	Paper	IF	Citations
59	Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. <i>Neuropsychopharmacology</i> , 2002 , 26, 744-55	8.7	141
58	The antidepressant-like effects of delta-opioid receptor agonists. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2006 , 6, 162-9		93
57	Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. <i>Psychopharmacology</i> , 2002 , 164, 42-8	4.7	75
56	The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. <i>Psychopharmacology</i> , 2005 , 180, 215-237	4.7	69
55	Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. <i>Brain Research</i> , 2006 , 1069, 172-81	3.7	68
54	The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 1337-48	4.7	67
53	Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. <i>Psychopharmacology</i> , 2005 , 182, 588-96	4.7	65
52	Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 309, 173-81	4.7	51
51	Patterns of nicotinic receptor antagonism: nicotine discrimination studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 339, 194-202	4.7	48
50	Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. <i>Molecular Pharmacology</i> , 2006 , 70, 1885-91	4.3	48
49	Multiple DSM-5 substance use disorders: A national study of US adults. <i>Human Psychopharmacology</i> , 2017 , 32, e2625	2.3	46
48	Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/ μ opioid receptor (DOR) antagonist ligands. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 2139-49	8.3	41
47	Development of a bioavailable μ opioid receptor (MOPr) agonist, μ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 3148-53	8.3	39
46	Differential behavioral tolerance to the delta-opioid agonist SNC80 (([+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide]) in Sprague-Dawley rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 315, 414-22	4.7	37
45	Selectivity and anti-Parkinson's potential of thiazolidinone RGS4 inhibitors. <i>ACS Chemical Neuroscience</i> , 2015 , 6, 911-9	5.7	34
44	Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. <i>European Journal of Pharmacology</i> , 2006 , 531, 151-9	5.3	34
43	Pre-existing differences in motivation for food and sensitivity to cocaine-induced locomotion in obesity-prone rats. <i>Physiology and Behavior</i> , 2015 , 152, 151-60	3.5	33

42	Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ Opioid Receptor (MOR) Agonists/ μ Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 8952-69	8.3	31
41	Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ Opioid Receptor (MOR)/ μ Opioid Receptor (DOR) Ligands. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 4985-98	8.3	30
40	In vivo effects of μ Opioid receptor agonist/ μ Opioid receptor antagonist peptidomimetics following acute and repeated administration. <i>British Journal of Pharmacology</i> , 2018 , 175, 2013-2027	8.6	25
39	Role of signalling molecules in behaviours mediated by the μ Opioid receptor agonist SNC80. <i>British Journal of Pharmacology</i> , 2018 , 175, 891-901	8.6	24
38	Tolerance to high-internalizing μ Opioid receptor agonist is critically mediated by arrestin 2. <i>British Journal of Pharmacology</i> , 2018 , 175, 3050-3059	8.6	23
37	A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. <i>Annals of Emergency Medicine</i> , 2009 , 54, 409-20	2.1	23
36	μ Opioid receptor coupling to G β plays an important role in opioid antinociception. <i>Neuropsychopharmacology</i> , 2011 , 36, 2041-53	8.7	23
35	Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ Opioid receptor/ μ Opioid receptor ligands. <i>ACS Chemical Neuroscience</i> , 2015 , 6, 1428-35	5.7	22
34	Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats. <i>Psychopharmacology</i> , 2008 , 200, 93-103	4.7	22
33	RB101-mediated protection of endogenous opioids: potential therapeutic utility?. <i>CNS Neuroscience & Therapeutics</i> , 2007 , 13, 192-205		21
32	Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects. <i>Neuropsychopharmacology</i> , 2017 , 42, 1940-1949	8.7	19
31	Single prolonged stress effects on sensitization to cocaine and cocaine self-administration in rats. <i>Behavioural Brain Research</i> , 2015 , 284, 218-24	3.4	18
30	Endogenous opioids as physiological antidepressants: complementary role of μ receptors and dopamine. <i>Neuropsychopharmacology</i> , 2012 , 37, 303-4	8.7	18
29	The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. <i>Psychopharmacology</i> , 2017 , 234, 29-39	4.7	16
28	The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum. <i>Neuropharmacology</i> , 2008 , 55, 755-62	5.5	16
27	Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5SO-(3-[35S]thio)triphosphate ([35S]GTP γ S) binding in brain slices from Sprague-Dawley rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 312, 1314-20	4.7	15
26	Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity μ /Delta Opioid Ligands for the Treatment of Pain. <i>ACS Chemical Neuroscience</i> , 2018 , 9, 1840-1848	5.7	11
25	The delta-opioid receptor agonist SNC80 [(+)-4-[α (R)- α -(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 324, 714-24	4.7	11

24	L-DOPA attenuates nicotine withdrawal-induced behaviors in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2011 , 98, 552-8	3.9	10
23	The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice. <i>Psychopharmacology</i> , 2016 , 233, 2479-87	4.7	9
22	Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism. <i>Neuropharmacology</i> , 2014 , 77, 19-27	5.5	9
21	Delta Opioid Receptors and Modulation of Mood and Emotion. <i>Handbook of Experimental Pharmacology</i> , 2018 , 247, 179-197	3.2	8
20	Pharmacological Properties of μ -Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 374, 319-330	4.7	7
19	Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 4193-4203	8.3	5
18	Preoperative ultra-rapid opiate detoxification for the treatment of post-operative surgical pain. <i>Medical Hypotheses</i> , 2015 , 84, 529-31	3.8	5
17	Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ Opioid Receptor (MOR)/ δ Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 1671-1683	8.3	5
16	Design, synthesis, and biological activity of 5-phenyl-1,2,5,6-tetrahydro-3,4-dihydropyridine analogues as potential antagonists of nicotinic acetylcholine receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017 , 27, 4350-4353	2.9	2
15	Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.. <i>Biomedicines</i> , 2022 , 10,	4.8	2
14	Comparison of the muscarinic antagonist effects of scopolamine and L-687,306. <i>Behavioural Pharmacology</i> , 2020 , 31, 359-367	2.4	2
13	Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 377, 336-345	4.7	2
12	The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 378, 287-299	4.7	2
11	Role of the guanine nucleotide binding protein, G_{i2} in the development of morphine tolerance and dependence. <i>Psychopharmacology</i> , 2018 , 235, 71-82	4.7	2
10	Role of hippocampal 5-HT _{1A} receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive G_{i2} protein. <i>Neuropharmacology</i> , 2018 , 141, 296-304	5.5	2
9	The protein kinase C β -selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats. <i>Psychopharmacology</i> , 2019 , 236, 3231-3242	4.7	1
8	The Protein Kinase C Inhibitor Tamoxifen Inhibits Neurochemical and Reinforcing Behavioral Effects of Amphetamine. <i>FASEB Journal</i> , 2015 , 29, 930.11	0.9	1
7	The selective delta opioid agonist SNC80 increases amphetamine-mediated release of dopamine. <i>FASEB Journal</i> , 2006 , 20, A676	0.9	

- 6 Amphetamine-sensitized rats demonstrate enhanced nicotine-stimulated locomotor activity and dopamine overflow. *FASEB Journal*, **2006**, 20, A677 0.9
- 5 Effects of agonists with mixed efficacy profiles at the mu and kappa opioid receptor on amphetamine-mediated dopamine release. *FASEB Journal*, **2008**, 22, 712.8 0.9
- 4 Protein Kinase C Inhibitors Attenuate Amphetamine-Stimulated Behaviors Through Direct and Indirect Mechanisms in Different Brain Regions. *FASEB Journal*, **2018**, 32, 820.2 0.9
- 3 Loss of RGS Control at G β Reveals a Balance Between Nociceptin and Mu-opioid Receptor Systems. *FASEB Journal*, **2019**, 33, 669.12 0.9
- 2 The Effects of RGS4 on Delta Opioid Receptor-mediated Behaviors in Mice. *FASEB Journal*, **2015**, 29, 929.7 0.9
- 1 The role of G β in mu-opioid signaling and antinociception. *FASEB Journal*, **2010**, 24, 583.5 0.9